Perioperative chemotherapy with FLOT regimen in patients with resectable gastric or gastroesophageal junction adenocarcinoma (SIEWERT type I–III). Experience of the N. N. Blokhin russian cancer research center
https://doi.org/10.18027/2224-5057-2022-12-4-5-13
Abstract
To date, gastric cancer patients still have a poor prognosis. Current endoscopic or surgical treatment modalities are radical only for early gastric cancer (T1). Curability dramatically declines as tumor invasion progresses and lymph node metastasеs appear. In Europe and North America, the 5-year overall survival rate of patients with stage T2–4 cancer is 20 % [1]. Combination therapy for gastric cancer is being extensively studied to improve the treatment outcomes [2–6]. Currently, perioperative chemotherapy with FLOT regimen is the mainstay of resectable gastric cancer treatment in Europe. FLOT4-AIO randomized study has shown that the FLOT regimen was associated with significant increase in the median overall survival (50 versus 35 months), disease-free survival (18 versus 30 months) and R0 resection rate compared to ECF / ECХ regimen.
In this work we evaluated the efficacy and toxicity of perioperative FLOT regimen in patients with gastric cancer and gastroesophageal junction cancer type I–III cT4aN0M0, cT1–4N + M0, using a prospective database of patients treated at the N. N. Blokhin Russian Cancer Research Center.
About the Authors
I. G. AvdyukhinRussian Federation
Ivan G. Avdyukhin, postgraduate student
Moscow
I. N. Peregorodiev
Russian Federation
Ivan N. Peregorodiev, MD, PhD, oncologist
Moscow
А. Е. Kalinin
Russian Federation
Alexey E. Kalinin, MD, PhD, Senior Researcher
Moscow
S. N. Nered
Russian Federation
Sergei N. Nered, MD, PhD, DSc, Senior Research Scientist
Moscow
N. S. Besova
Russian Federation
Natalia S. Besova, MD, PhD, Senior Research Scientist
Moscow
А. А. Tryakin
Russian Federation
Alexey A. Tryakin, MD, PhD, DSc, Deputy Director for Research, N. N. Trapeznikov Research Institute of Clinical Oncology
Moscow
Е. V. Artamonova
Russian Federation
Elena V. Artamonova, MD, PhD, DSc, Head of the Department
Moscow
Т. А. Titova
Russian Federation
Tatiana А. Titova, MD, PhD, oncologist
Moscow
Е. S. Obarevich
Russian Federation
Ekaterina S. Obarevich, oncologist, Chemotherapy Department
Moscow
Е. О. Ignatova
Russian Federation
Ekaterina O. Ignatova, MD, PhD, Researcher
Moscow
N. А. Kozlov
Russian Federation
Nikolay A. Kozlov, MD, PhD, pathologist
Moscow
О. V. Rossomakhina
Russian Federation
Olesya M. Rossomahina, Senior Lecturer
Lugansk, Lugansk People's Republic
N. А. Shishkina
Russian Federation
Nina A. Shishkina, radiologist
Moscow
Е. S. Kolobanova
Russian Federation
Evgeniya S. Kolobanova, Researcher
Moscow
О. А. Malikhova
Russian Federation
Olga А. Malikhovа, MD, PhD, DSc, Head of the Department
Moscow
М. G. Abgaryan
Russian Federation
Mikael G. Abgaryan, MD, PhD, Senior Researcher
Moscow
М. P. Nikulin
Russian Federation
Maksim P. Nikulin, MD, PhD, Senior Researcher
Moscow
P. P. Arkhiri
Russian Federation
Petr P. Arkhiri, MD, PhD, oncologist
Moscow
L. А. Vashakmadze
Russian Federation
Levan А. Vashakmadze, MD, PhD, DSc, Professor, Senior Research Advisor
Moscow
S. Hengyan
Russian Federation
Sun Hengyan, postgraduate student
Moscow
E. А. Suleimanov
Russian Federation
Elkhan A. Suleimanov, MD, PhD
Grozny
I. S. Stilidi
Russian Federation
Ivan S. Stilidi, Academician of the Russian Academy of Sciences, MD, PhD, DSc, Professor, Director
Moscow
References
1. Reim D, Loos M, Vogl F, et al. Prognostic implications of the seventh edition of the International Union Against Cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 2013 ; 31 : 263–71.
2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006 ; 355 : 11–20.
3. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011 ; 29 : 1715–21.
4. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012 ; 366 : 2074–84.
5. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo (radio) therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 2013 ; 49 : 3149–58.
6. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010 ; 28 : 5210–18.
7. Stark AP, Ikoma N, Chiang YJ et al. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct ; 26 (11) : 3602–3610. doi : 10.1245/s10434-019-07638-8. Epub 2019 Jul 26. PMID : 31350645.
8. Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011 ; 253 : 934–39.
9. Alderson D, Langley RE, Nankivell MG, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). Proc Am Soc Clin Oncol 2015 ; 33 (suppl) : 4002 (abstr).
10. Cunningham D, Smyth E, Stenning S, et al. Peri-operative chemotherapy±bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948). Eur J Cancer 2015 ; 51 (suppl 3) : S400.
11. Donohoe CL, O'Farrell NJ, Grant T, et al. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg 2013 ; 258 : 784–92.
Review
For citations:
Avdyukhin I.G., Peregorodiev I.N., Kalinin А.Е., Nered S.N., Besova N.S., Tryakin А.А., Artamonova Е.V., Titova Т.А., Obarevich Е.S., Ignatova Е.О., Kozlov N.А., Rossomakhina О.V., Shishkina N.А., Kolobanova Е.S., Malikhova О.А., Abgaryan М.G., Nikulin М.P., Arkhiri P.P., Vashakmadze L. ., Hengyan S., Suleimanov E.А., Stilidi I.S. Perioperative chemotherapy with FLOT regimen in patients with resectable gastric or gastroesophageal junction adenocarcinoma (SIEWERT type I–III). Experience of the N. N. Blokhin russian cancer research center. Malignant tumours. 2022;12(4):5-13. (In Russ.) https://doi.org/10.18027/2224-5057-2022-12-4-5-13